Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly

Insulin-Like Growth Factor I: Pros and Cons of a Bioassay

(2011) J.A.M.J.L. Janssen   Hormone Research in Paediatrics

Insulin and its analogs: actions via insulin and IGF receptors

(2010) R. Vigneri et al.   ACTA DIABETOLOGICA

IGF-I Bioactivity in an Elderly Population: Relation to Insulin Sensitivity, Insulin Levels, and the Metabolic Syndrome

(2010) M. P. Brugts et al.   DIABETES

Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients

(2010) E. Mannucci et al.   DIABETES CARE

Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling

(2010) L. Sciacca et al.   DIABETOLOGIA

Metformin: Taking away the candy for cancer?

(2010) Mathilde Jalving et al.   EUROPEAN JOURNAL OF CANCER

Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir

(2010) A.J. Varewijck et al.   GROWTH HORMONE & IGF RESEARCH

AMP-Activated Protein Kinase Inhibits IGF-I Signaling and Protein Synthesis in Vascular Smooth Muscle Cells via Stimulation of Insulin Receptor Substrate 1 S794 and Tuberous Sclerosis 2 S1345 Phosphorylation

(2010) Junyu Ning et al.   MOLECULAR ENDOCRINOLOGY

Treatment with insulin glargine (Lantus®) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells

(2010) Doris Mayer et al.   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

Insulin Glargine and NPH Insulin Increase to a Similar Degree Epithelial Cell Proliferation and Aberrant Crypt Foci Formation in Colons of Diabetic Mice

(2010) Jutta M. Nagel et al.   Hormones & Cancer

Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells

(2009) Doron Weinstein et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Does diabetes therapy influence the risk of cancer?

(2009) U. Smith et al.   DIABETOLOGIA

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

(2009) J. M. Jonasson et al.   DIABETOLOGIA

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

(2009) H. M. Colhoun et al.   DIABETOLOGIA

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

(2009) C. J. Currie et al.   DIABETOLOGIA

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

(2009) L. G. Hemkens et al.   DIABETOLOGIA

Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease

(2009) Antonino Belfiore et al.   ENDOCRINE REVIEWS

The Role of Insulin-Like Growth Factor (IGF) Binding Protein-2 in the Insulin-Mediated Decrease in IGF-I Bioactivity

(2009) Ayman M. Arafat et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer

(2008) Pamela J. Goodwin et al.   Clinical Breast Cancer

Beyond the Era of NPH Insulin—Long-Acting Insulin Analogs: Chemistry, Comparative Pharmacology, and Clinical Application

(2008) D.R. Owens et al.   Diabetes Technology & Therapeutics

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

(2008) D. M. Nathan et al.   DIABETOLOGIA

Normal Values of Circulating Insulin-Like Growth Factor-I Bioactivity in the Healthy Population: Comparison with Five Widely Used IGF-I Immunoassays

(2008) Michael P. Brugts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM